Australia's PYC Therapeutics rises on EU orphan drug status
27/04/2026 04:23
** PYC Therapeutics PYC.AX rises as much as 2.3% to A$1.325 ** Stock set for third straight session of gains ** Biotech co receives Orphan Drug Designation from European Medicines Agency for its genetic vision loss treatment drug ** YTD, PYC down 18.6% (Reporting by Aamir Sheik Khalid in Bengaluru) ((Aamir.SheikKhalid@thomsonreuters.com))
Recent news on PYC Therapeutics
See all newsAustralia's PYC Therapeutics rises on EU orphan drug status
Brief: PYC Therapeutics Posts HY Revenues From Ordinary Activities A$11.0 Million
Brief: PYC Therapeutics Announces Raising Up To A$653 Million
Brief: PYC Therapeutics Seeks Trading Halt
Brief: PYC Therapeutics Says Rohan Hockings Re-Appointed As Managing Director